Connexion
E-mail
Mot de passe
Afficher le mot de passe
Retenir
Mot de passe oublié ?
Devenir membre gratuitement
Inscription
Inscription
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Paramètres
Paramètres
Cotations dynamiques 
OFFON

EDITAS MEDICINE, INC.

(EDIT)
  Rapport
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFondsCommunauté 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur EDITAS MEDICINE, INC.
12/11Editas Medicine Presents Preclinical Data on Novel Engineered iPSC-derived NK Cells for..
12/11Editas Medicine Presents Preclinical Data on Novel Engineered iPSC-derived NK Cells for..
09/11EDITAS MEDICINE, INC. Management's Discussion and Analysis of Financial Condition and ..
08/11Health Care Stocks Adding Support Shortly Before Monday Close
08/11Health Care Stocks Edging Higher in Monday Trading
08/11Editas Medicine Swings to Q3 Loss as Revenue Declines; Beats Street Forecast
08/11Editas Medicine Announces Third Quarter 2021 Results and Business Updates - Form 8-K
08/11EDITAS : Q3 Earnings Snapshot
08/11Editas Medicine Announces Third Quarter 2021 Results and Business Updates
04/11Editas Medicine to Present Data Demonstrating Progress Towards Transformative Gene Edit..
28/10EDITAS MEDICINE, INC. : Change in Directors or Principal Officers (form 8-K)
28/10Editas Medicine Names Bernadette Connaughton to Board of Directors
28/10Editas Medicine Names Bernadette Connaughton to Board of Directors
25/10EDITAS MEDICINE : to Host Conference Call Discussing Third Quarter 2021 Results and Corpor..
20/10INSIDER SELL : Editas Medicine
20/10EDITAS MEDICINE : Clinical Data from Editas Medicine's Ongoing Phase 1/2 BRILLIANCE Clinic..
08/10EDITAS MEDICINE : Shares Fall in Afternoon Trading
07/10EDITAS MEDICINE : to Present Preclinical Data on Novel Engineered iPSC Derived NK Cells fo..
30/09EDITAS MEDICINE : to Present at Chardan's 5th Annual Genetic Medicines Conference
29/09Health Care Stocks Easing Slightly From Intra-Day Highs Near Close
29/09EDITAS MEDICINE : Shares Drop After Mixed Results in Blindness Treatment Trial
29/09EDITAS MEDICINE : Gene Editing Candidate Shows Potential in Blindness Trial
29/09EDITAS MEDICINE : Review of BRILLIANCE Phase 1/2 Single Ascending Dose Study of EDIT-101 P..
29/09EDITAS MEDICINE : Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIAN..
29/09EDITAS MEDICINE, INC. : Regulation FD Disclosure, Other Events, Financial Statements and E..
29/09EDITAS MEDICINE : Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIAN..
29/09Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIA..
13/09NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
08/09EDITAS MEDICINE, INC. : Change in Directors or Principal Officers (form 8-K)
08/09Editas Medicine Names Emma Reeve to Board of Directors
08/09Editas Medicine, Inc. Names Emma Reeve to Board of Directors
07/09EDITAS MEDICINE : Initial Clinical Data from Editas Medicine's BRILLIANCE Clinical Trial o..
07/09Editas Medicine, Inc. Announces Initial Clinical Data from Clinical Trial of EDIT-101 f..
02/09EDITAS MEDICINE : to Participate in Upcoming Investor Conferences
20/08EDITAS MEDICINE PRESENTS DATA ON NEW : CRISPR Frontiers Meeting
20/08Editas Medicine, Inc. Presents Data on New Sleek Gene Editing Technology
06/08NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
05/08EDITAS MEDICINE : Management's Discussion and Analysis of Financial Condition and Results ..
04/08EDITAS MEDICINE : Q2 Loss Widens, Revenue Declines
04/08EDITAS MEDICINE : Announces Second Quarter 2021 Results and Business Updates (Form 8-K)
04/08Editas Medicine, Inc. Announces Recent Achievements
04/08EDITAS : Q2 Earnings Snapshot
04/08EDITAS MEDICINE : Announces Second Quarter 2021 Results and Business Updates
04/08Editas Medicine, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 20..
29/07EDITAS MEDICINE : and IDT Announce Publication in Nature Communications of Research Data S..
28/07Editas Medicine to Host Conference Call Discussing Second Quarter 2021 Results and Corp..
27/07REACH : Daily Mirror publisher says digital sales push trading ahead of expectations
26/07EDITAS MEDICINE : Names Bruce E. Eaton, Ph.D., as Executive Vice President and Chief Busin..
26/07Editas Medicine, Inc. Announces Executive Changes
28/06SECTOR UPDATE : Health Care Stocks Catch Late Bounce to Plus Side
28/06SECTOR UPDATE : Health Care Stocks Slipping Underwater Again in Recent Trade
23/06EDITAS MEDICINE : Begins Enrollment in First Pediatric Cohort in Study of Drug Candidate f..
23/06Editas Medicine Announces Enrollment of the First Pediatric Cohort in the BRILLIANCE Cl..
23/06Editas Medicine Announces Enrollment of the First Pediatric Cohort in the Brilliance Cl..
15/06Editas Medicine Reports Inducement Grants to New Chief Scientific Officer and Chief Reg..
14/06EDITAS MEDICINE : Strengthens Executive Leadership Team to Advance Pipeline and Support Lo..
14/06Editas Medicine, Inc. Names Chi Li as Senior Vice President and Chief Regulatory Office..
11/06Editas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Pha..
11/06Editas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Pha..
08/06EDITAS MEDICINE, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
21/05EDITAS MEDICINE : Corporate Governance Presentation
14/05EDITAS MEDICINE, INC. : Entry into a Material Definitive Agreement, Financial Statements a..
06/05EDITAS MEDICINE : Management's Discussion and Analysis of Financial Condition and Results ..
06/05Daily Mirror publisher expects to exceed annual profit target on digital power
05/05EDITAS MEDICINE : Posts Wider Q1 Net Loss, Names Chief Scientific Officer
05/05EDITAS : Q1 Earnings Snapshot
05/05Editas Medicine Announces First Quarter 2021 Results and Update
05/05Editas Medicine Names Mark S. Shearman, Ph.D., as Chief Scientific Officer
05/05Editas Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 20..
05/05Editas Medicine, Inc. Names Mark S. Shearman as Chief Scientific Officer
04/05Editas Medicine to Present Preclinical Data Demonstrating Progress in Development of Ge..
01/05Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene ..
28/04Editas Medicine to Host Conference Call Discussing First Quarter 2021 Results and Corpo..
21/04Certain Stock Options of Editas Medicine, Inc. are subject to a Lock-Up Agreement Endin..
21/04Certain Common Stock of Editas Medicine, Inc. are subject to a Lock-Up Agreement Ending..
1  2  3  4  5  6Suiv.
Prochain événement sur EDITAS MEDICINE, INC.